Stiripentol

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy, Dravet Syndrome, Developmental and Epileptic Encephalopathies

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Also in development:Primary Hyperoxaluria Type 1 · Phase 3 · investigational in the US

Also approved (1)
EU
  • Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.
Product first approved 2007EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Primary Hyperoxaluria Type 1
Phase 2 (1)
Other / comorbidity
NCT03819647 · Biocodex
2019-05-21 – 2021-03-08 · Primary Hyperoxaluria
What this study did
Phase 1 (3)
Developmental and Epileptic Encephalopathies
Other / comorbidity
NCT05735951 · Biocodex
2023-07-24 – 2024-11-30 · Chronic Renal Insufficiency
What this study did
NCT03866928 · Biocodex
2019-02-12 – 2019-04-05 · Healthy Volunteers
What this study did
Phase 4 (1)
Other / comorbidity
NCT05419180 · Biocodex
2022-10-13 – 2024-06-13 · Pharmacoresistant Focal Epilepsies
What this study did

Competitive landscape

This mechanism is crowded: 14 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Stiripentol: this drugApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidReliable signal
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001).
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022).
RufinamideApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
KH607
Phase 3(overall)
Small moleculeGABA-A receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication
GlyphAllo (allopregnanolone Prodrug) (SPT-300)
Phase 2(overall)
Small moleculeGABA-A receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
HS-10353
Phase 2(overall)
Small moleculeGABA-A receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Remimazolam
Phase 1(overall)
Small moleculeGABA-A receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Compare side by side

4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Stiripentol to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
August 2030 (1)
Phase 3Primary Hyperoxaluria Type 1Recruiting
Est. primary completion 2030-08 · NCT06465472 · CT.gov ↗
What to watch

See the full readout calendar ↗